Structural and functional characterization of fosfomycin resistance conferred by FosB from Enterococcus faecium

Vanessa Wiltsie1, Skye Travis1, Madeline R Shay1

  • 1Department of Chemistry & Biochemistry, The University of Alabama, Tuscaloosa, Alabama, USA.

Insights

Enterococcus faecium causes hospital infections. Researchers found its FosB enzyme uses L-cysteine, not BSH, to resist fosfomycin, offering new targets for drug development.

Area of Science:

  • Microbiology
  • Biochemistry
  • Structural Biology

Background:

  • Enterococcus faecium, a Gram-positive pathogen, is a primary cause of hospital-acquired vancomycin-resistant enterococci (VRE) infections.
  • E. faecium exhibits extensive multidrug resistance, leading to over two million infections annually in the US.
  • FosB is a key fosfomycin resistance enzyme in Gram-positive pathogens, typically acting as a manganese-dependent bacillithiol transferase.

Purpose of the Study:

  • To investigate the substrate specificity and mechanism of the FosB enzyme from E. faecium (FosB Ef).
  • To determine the three-dimensional structure of FosB Ef in complex with fosfomycin.
  • To identify structural determinants responsible for altered substrate selectivity within the FosB enzyme family.

Main Methods:

  • Kinetic analysis to determine enzyme substrate utilization.
  • X-ray crystallography to resolve the 3D structure of FosB Ef-fosfomycin complex.
  • Sequence similarity network (SSN) analysis of the FosB family.

Main Results:

  • FosB Ef functions as a manganese-dependent L-cysteine transferase, differing from other characterized FosB enzymes that use bacillithiol.
  • The X-ray crystal structure of FosB Ef complexed with fosfomycin was determined at 2.0 kA resolution.
  • SSN analysis identified three non-conserved residues potentially responsible for the divergent substrate selectivity in the FosB family.

Conclusions:

  • FosB Ef exhibits unique substrate selectivity, utilizing L-cysteine instead of BSH.
  • The structural and functional characterization of FosB Ef provides a basis for developing novel inhibitors.
  • Targeting FosB Ef could enhance the efficacy of fosfomycin in treating resistant enterococcal infections.